Advani Anjali S
1Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, and.
Hematology Am Soc Hematol Educ Program. 2013;2013:131-7. doi: 10.1182/asheducation-2013.1.131.
The prognosis of adult acute lymphoblastic leukemia (ALL) remains poor and novel treatment strategies are needed. Antibody-based therapies represent such an approach. ALL cells express various surface antigens that are targets for monoclonal antibodies. This review focuses on 4 major classes of antibody therapy: (1) naked antibodies, (2) T-cell-engaging bispecific single-chain antibodies, (3) immunoconjugates/immunotoxins, and (4) chimeric antigen receptors. Preclinical and clinical data are reviewed. This area of research represents an exciting new approach to help improve the outcome of this disease. Several clinical trials are currently incorporating this therapy in the treatment of newly diagnosed and relapsed adult ALL patients.
成人急性淋巴细胞白血病（ALL）的预后仍然很差，需要新的治疗策略。基于抗体的疗法就是这样一种方法。ALL细胞表达多种作为单克隆抗体靶点的表面抗原。本综述聚焦于4大类抗体疗法：（1）裸抗体，（2）T细胞接合双特异性单链抗体，（3）免疫偶联物/免疫毒素，以及（4）嵌合抗原受体。对临床前和临床数据进行了综述。该研究领域代表了一种有助于改善这种疾病治疗结果的令人兴奋的新方法。目前有几项临床试验正在将这种疗法纳入新诊断和复发的成人ALL患者的治疗中。
